Create Account
Log In
Dark
chart
exchange
Premium
Terminal
Screener
Stocks
Crypto
Forex
Trends
Depth
Close
Check out our Level2View


bluebird bio, Inc. (BLUE) announced its intent to separate its severe genetic disease and oncology businesses into independent publicly traded companies. bluebird bio, Inc. will retain focus on severe genetic disease and will launch its oncology business as a new entity.


RTTNews | Jan 11, 2021 06:44AM EST

06:44 Monday, January 11, 2021 (RTTNews.com) - bluebird bio, Inc. (BLUE) announced its intent to separate its severe genetic disease and oncology businesses into independent publicly traded companies. bluebird bio, Inc. will retain focus on severe genetic disease and will launch its oncology business as a new entity.

Upon completion of the separation, current chief bluebird, Nick Leschly, will lead Oncology Newco as Chief Executive Officer and will take on the role of Executive Chair for bluebird bio, Inc. Current President of the severe genetic disease business, Andrew Obenshain will continue his leadership as Chief Executive Officer of bluebird bio, Inc.

Read the original article on RTTNews ( https://www.rttnews.com/3159273/bluebird-bio-s-board-approves-plan-to-separate-into-two-companies-quick-facts.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved






Share
About
Pricing
Policies
Markets
API
Info
tz UTC-4
Connect with us
ChartExchange Email
ChartExchange on Discord
ChartExchange on X
ChartExchange on Reddit
ChartExchange on GitHub
ChartExchange on YouTube
© 2020 - 2025 ChartExchange LLC